2curex

- because cancer patients are individuals

Availability of IndiTreat ®

Maarten van der Linden, MBA
2cureX Chief Business Officer

The IndiTreat® Sensitivity Test is now available to all clinics in Europe.

Empowering oncologists with CE IVD verified patient-derived microtumors, used for the prediction of resistance and sensitivity to drugs for some major cancers.

- because cancer patients are individuals

2curex

IndiTreat® can be used in 3 cancer entities

Colorectal Cancer
European CE-IVD approved



Ovarian Cancer
Multi-center clinical
Validation trials ongoing

Pancreatic Cancer
Multi-center clinical
Validation trials ongoing

- because cancer patients are individuals

IndiTreat® test process



- because cancer patients are individuals

2curex

IndiTreat® identifies the best cancer treatment

The Functional Precision Medicine (FPM) test IndiTreat® measures drug sensitivity and resistance in each cancer patient.

Our method is based on a small tumor biopsy taken from a patient which is sent to a central 2cureX lab for analysis.



The power of functional and genomic precision



IndiTreat supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity

Safe transport of viable biopsies is achieved through a continuous cold chain with distribution partners from your clinic to our laboratories

- because cancer patients are individuals

2curex

IndiTreat® – focused on improving patient outcomes

- IndiTreat® empowers oncologists with CE IVD verified patient-derived microtumors
- Predicts resistance and sensitivity to cancer drugs
- Select the most appropriate treatment, in accordance with guidelines
- Improve patient quality of life through *in vitro* testing of drug efficacy on the individual patient

- because cancer patients are individuals

The physician receives a detailed drug sensitivity report via email after approximately 2 weeks.

- because cancer patients are individuals

2curex

Expert consultation

Dr. Henrik Harling (CMO) is available for detailed consultation of the report results via an online conference, supporting you throughout the process.

The power of precision.
For every Oncologist.
Today.

- because cancer patients are individuals